In this application our overall hypothesis is that HIV-1 vectors can be developed that are both safe and effective for delivery of genes to protect cells from HIV-1 infection. The use of gene therapy in humans requires, first, a better understanding of the parameters necessary for efficient transduction, transplant, marking and gene expression. Second, we must utilize this information to model gene therapy for specific human diseases in this case, H IV-1 disease. The primary advantage of HIV-1 based vectors is that they are derived from a virus which has evolved to efficiently infect human cells. However, this property is also the basis of the major reservation regarding the safety of these vectors. Since we believe there are many advantages to the use of lentiviral vectors, particularly in the context of HIV-1 disease, it is critical that if lentiviral vectors are to move forward into the human clinical arena, that their substantial theoretical advantages be documented in primate model systems. We propose to utilize the SCID-hu model for human CD34+ T-progenitor cell transplant and the rhesus macaque CD34+ cell autologous transplant system. As outlined in our Preliminary Studies, we successfully developed protocols to exploit these model systems to better understand the properties of HIV-1 vectors. We also developed a novel inducible HIV-1 vector (DAt1 ru) which itself inhibits HIV-1 replication in the absence of other anti-HIV-1 genes. We propose to understand the mechanism of action of this vector and then test this vector using the two primate model systems described above.
The specific aims are: 1) Determine the mechanism by which the inducible HIV-1 based vector inhibits HIV-1 replication. 2) Develop further understanding of the requirements for efficient HIV-1 vector transduction, transplantation, multi-lineage marking, gene expression, and immune response. 3) Based upon the results of Aims 1 and 2, test the effectiveness of the best anti-HIV gene therapeutic vectors to inhibit HIV-1 1/SIV replication in in vivo model systems of SCID-hu mice and rhesus macaque.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI039975-08
Application #
6828315
Study Section
Special Emphasis Panel (ZRG1-AARR-1 (01))
Program Officer
Voulgaropoulou, Frosso
Project Start
1997-04-01
Project End
2006-11-30
Budget Start
2004-12-01
Budget End
2006-11-30
Support Year
8
Fiscal Year
2005
Total Cost
$305,000
Indirect Cost
Name
University of California Los Angeles
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Pang, Shen; Pokomo, Lauren; Chen, Kevin et al. (2014) High-throughput screening of effective siRNAs using luciferase-linked chimeric mRNA. PLoS One 9:e96445
Shimizu, Saki; Kamata, Masakazu; Kittipongdaja, Panyamol et al. (2009) Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5. Genet Vaccines Ther 7:8
Kamata, Masakazu; Susanto, Melisa T; Chen, Irvin S Y (2009) Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells. J Gene Med 11:103-11
Morizono, Kouki; Xie, Yiming; Helguera, Gustavo et al. (2009) A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med 11:655-63
Morizono, Kouki; Pariente, Nonia; Xie, Yiming et al. (2009) Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J Gene Med 11:549-58
Liang, Min; Pariente, Nonia; Morizono, Kouki et al. (2009) Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells. J Gene Med 11:185-96
Pariente, Nonia; Mao, Si-Hua; Morizono, Kouki et al. (2008) Efficient targeted transduction of primary human endothelial cells with dual-targeted lentiviral vectors. J Gene Med 10:242-8
An, Dong Sung; Donahue, Robert E; Kamata, Masakazu et al. (2007) Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A 104:13110-5
Pariente, Nonia; Morizono, Kouki; Virk, Mandeep S et al. (2007) A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther 15:1973-81
An, Dong Sung; Poon, Betty; Ho Tsong Fang, Raphael et al. (2007) Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 14:391-6

Showing the most recent 10 out of 23 publications